Orthopedic Biologics Distributor Serving Detroit, Michigan

What a Detroit orthopedic group typically asks for before ordering

An orthopedic practice evaluating a new biologics vendor usually starts with the paper trail: the certificate of analysis for the lot being purchased, a donor eligibility summary, and the lot release record confirming third-party sterility testing and the quarantine hold that preceded release. We make all three available to any verified account before the first shipment goes out.

Surgery centers that already maintain a vendor-credentialing file for other supplies tend to add our documentation to that same file rather than standing up a separate process.

Account setup and NPI verification

We open accounts only for licensed physicians and for clinics ordering under physician supervision, and every account is matched against an NPI number before activation. A practice administrator can begin the setup, but the account is held under the supervising physician's name.

Verified accounts can request a peer-to-peer call to review product documentation and lot structure. These calls stay on sourcing and paperwork; they do not cover dosing, technique, or patient selection, which remain the treating physician's responsibility.

Receiving cold-chain shipments in the Midwest

Cryopreserved formats ship overnight on dry ice in validated containers and are held at -80 degrees Celsius before shipment. A Detroit practice should have freezer capacity confirmed before the delivery window, since the product needs to move into storage promptly on arrival rather than sit at a front desk. Lyophilized formats are shelf-stable and ship without the same cold-chain handling.

Each unit carries its own lot identifier. We recommend logging that identifier at the patient-record level so a practice can trace a specific unit back to its lot if a question comes up later.

Checking regulatory posture with your own board and counsel

Whether a specific Wharton's jelly product and intended use meets the minimal-manipulation and homologous-use criteria under the federal HCT/P framework is a determination for your practice and its legal counsel, not something a supplier can certify. Exosome products are a separate case: there are no FDA-approved exosome products, and they are generally regulated as biologic drugs.

We recommend Detroit practices confirm their marketing language and intended-use documentation with the Michigan medical board and their own healthcare counsel, given increased FDA enforcement attention toward distributor and clinic website claims in 2026.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.